The growing shift from bulk tissue profiling to single-cell resolution is reshaping biomedical research, and service providers are racing to supply the tools needed to dissect cellular heterogeneity. Creative Biolabs has expanded its advanced single-cell multi-omics and RNA sequencing solutions, a move that could lower barriers for laboratories tackling difficult samples and multimodal analysis. The upgraded suite provides end-to-end services, from single-cell transcriptome profiling to integrated multimodal and multi-omics workflows, targeting oncology, immunology, and neuroscience.
The importance of this expansion lies in the persistent bottlenecks that have limited single-cell studies. Many tissues are fibrous, flash-frozen, or biobanked, making standard enzymatic dissociation problematic. Such processing can damage cells, trigger stress responses, or cause selective loss of fragile cell types. To address this, Creative Biolabs offers single-cell RNA sequencing services for high-throughput transcriptomic profiling of thousands of individual cells from fresh specimens. For challenging tissues like human brain, myocardium, or clinical biopsies, the company provides an optimized single-cell nuclei RNA sequencing service that isolates intact nuclei, bypassing harsh dissociation while retaining informative nuclear RNA profiles.
Beyond transcriptomics, the company has advanced its high-throughput single-cell multi-omics service, which allows simultaneous interrogation of genomic variations, epigenomic landscapes such as chromatin accessibility, cell surface proteomics via CITE-seq, and transcriptomes within the same single cells. This integration is significant because cellular identity is orchestrated across multiple regulatory layers. By linking epigenetic regulation and genomic alterations directly to gene expression, researchers can construct multi-dimensional cellular atlases and uncover therapeutic targets with greater clarity.
A senior scientist at Creative Biolabs stated, "Understanding biology at single-cell and single-nucleus resolution is no longer a luxury—it is fundamental to precision medicine and biomarker discovery. Our goal is to provide researchers with a seamless, modular analytical ecosystem that transforms difficult biological samples into reliable, high-dimensional datasets with rigorous bioinformatics support." The implication for drug discovery and clinical translation is substantial: reliable single-cell data can reveal rare cell subpopulations, characterize tumor microenvironments, and trace lineage trajectories, all of which are essential for developing targeted therapies.
The expansion also reflects a broader trend in life sciences toward integrated, multi-omic readouts supported by advanced microfluidics, stringent quality control, and tailored bioinformatics. As academic and biopharmaceutical teams increasingly require scalable, high-resolution solutions, service providers that can handle archival and fragile samples may become critical partners in translational research.
